[Drug-induced cardiomyopathy].
Takemoto
Yasuhiko
Y
Department of Internal Medicine and Cardiology, Osaka City University Medical School.
Yoshiyama
Minoru
M
D018943:Anthracyclines / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy; D003520:Cyclophosphamide / Q000009:adverse effects; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects; D017239:Paclitaxel / Q000009:adverse effects; D013997:Time Factors; D000068878:Trastuzumab
D018943:Anthracyclines; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D016898:Interferon-alpha; D003520:Cyclophosphamide; D000068878:Trastuzumab; D017239:Paclitaxel